Terms: = Lung cancer AND IKZF1, LyF-1, 10320, ENSG00000185811, Q13422, Hs_54452, hIk-1, ZNFN1A1, IKAROS AND Treatment
5 results:
1. Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer.
Xu Y; Yan J; Zhou C; Wu L; Wang H; Zhao J; Zhou M; Wang J; Zheng X; Zhang L; Jiang K; Zheng X; Miao Q; Wu S; Zou Z; Lian R; He Y; Chen R; Yang S; Li Y; Chen S; Lin G
Eur J Cancer; 2023 Jul; 188():81-89. PubMed ID: 37201385
[TBL] [Abstract] [Full Text] [Related]
2. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
[TBL] [Abstract] [Full Text] [Related]
3. [Clinical analysis of 12 cases of acute myeloid leukemia complicated with synchronous primary solid tumor].
Mi RH; Dang HB; Chen L; Han YL; Wang MF; Zhang YL; Chen L; Li DB; Wei XD
Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(42):3323-3327. PubMed ID: 33202495
[No Abstract] [Full Text] [Related]
4. Overexpression of Aiolos promotes epithelial-mesenchymal transition and cancer stem cell-like properties in lung cancer cells.
Hung JJ; Kao YS; Huang CH; Hsu WH
Sci Rep; 2019 Feb; 9(1):2991. PubMed ID: 30816208
[TBL] [Abstract] [Full Text] [Related]
5. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract] [Full Text] [Related]
